TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06350318: Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas

Sponsor: H. Lee Moffitt Cancer Center and Research Institute · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 43 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$14,784,000

Rescue Site Savings

+$9,748,200

Unlock Full NCT06350318 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06350318 Rescue Dossier →